Thyme Care’s Post

I’m excited to share that Florida Blue, in collaboration with GuideWell Health, has launched a new, comprehensive oncology care model to enhance cancer care for thousands of our myBlue members. This initiative is a reflection of our commitment to delivering high-quality, affordable, and patient-centered care. How it works: Jointly developed with Sanitas Medical Center and The Oncology Institute, this innovative program ensures: 1) Seamless collaboration between primary care physicians and oncology specialists. 2) Personalized treatment plans tailored to each patient’s unique needs and preferences. 3) Comprehensive support addressing physical, mental, and social well-being. With TOI’s expertise in value-based oncology care and Sanitas’ holistic approach to primary care (a key part of GuideWell Health’s integrated delivery system), this program is setting a new standard for how cancer care is delivered in Florida. Why it matters: Navigating a cancer diagnosis is one of life’s most challenging experiences. By fostering better communication and coordination across care teams, we’re reducing stress for patients and their families, empowering them to focus on healing and improving their quality of life. At Florida Blue and GuideWell Health, we’re transforming healthcare by making it more accessible, affordable, and seamlessly connected. This oncology care program is a shining example of that mission in action.

Exciting news in the fight against colorectal cancer! Guardant Health’s Shield™ blood test has received FDA approval as a primary screening option for colorectal cancer, making it the first blood test to meet performance requirements for Medicare coverage. This innovative test offers a simple, convenient, and non-invasive alternative to traditional screening methods, potentially increasing screening rates and saving more lives through early detection. At Lampgen Clinical Research, we recognize the impact of such advancements in oncology. As a leading staffing firm, we are committed to providing expert oncology CRAs to ensure your cancer clinical trials are monitored with the highest standards of ICH/GCP and industry expertise. We take pride in supporting companies pioneering these critical developments in cancer care. #OncologyResearch #ClinicalTrials #CancerScreening #ColorectalCancer #FDAApproval #MedicareCoverage #PrecisionOncology #GuardantHealth #EarlyDetection #HealthcareInnovation #LampgenClinicalResearch #CRAs #CancerAwareness ⛓️💥 https://lnkd.in/eWJw45E9

If you are over 45, you should be screened for colorectal cancer. I know. It's not as fun as it sounds. But caught early, it can be dealt with and you can move on with your life. Caught late, and it's going to affect your life. Today, the FDA approved a blood test, which is another option for screening. Talk to your doc about getting screened. Details: https://lnkd.in/gfMSutB4

Global Patient Survey: Can a simple share help empower kidney cancer patients?   In January 2023, I took the role of Chair of the Medical Advisory Board of the International Kidney Cancer Coalition (IKCC). We are a group of clinical experts from around the globe with a mandate to provide scientific and clinical expertise to IKCC and support its commitment to evidence-based leadership and patient engagement.   As such, a focus has been increasing clinician-patient engagement through leadership and training programs, including our Clinical Leadership Workshops where clinicians and patient advocacy leaders come together to better understand patient engagement and how it improves patient outcomes.   While we continue to scale up the training program, how can we, members of the kidney cancer community, take steps to ensure our patients’ voices, values and experiences are included in all decisions about treatment and care? When we are already operating in resource- and time-strapped health systems, it can seem overwhelming.   But may I offer you a suggestion?   If you work with people affected by kidney cancer – patients, survivors or caregivers – please consider telling them about the IKCC Global Patient Survey on Kidney Cancer and Growths and encourage then to participate. The biennial survey is an opportunity for people to share their experiences and voice their insights related to access to care, quality of life, involvement in clinical trials, shared decision-making and more.    Since the first survey was launched in 2018, results have been instrumental to IKCC’s evidence-based initiatives. There have been published research papers, clinical conference presentations, educational resources, and more. Through these projects and programs, patients’ perspectives are reaching healthcare providers, government bodies and decision makers, industry partners and other stakeholders who influence patient care.   By encouraging survey participation, and investing just 20 minutes of their time, you are empowering the people in your clinical community. In one of 16 available languages, they can have their real-life experiences heard, counted and considered. And ultimately, they can help improve the lives of people affected by kidney cancer globally.   The survey is open till 15 November. You can find the IKCC Global Patient Survey on Kidney Cancer and Growths here: https://bit.ly/ikcc2024GPS

FDA approves first colorectal cancer blood test As colorectal cancer becomes more frequent also in younger ages (+45 years) a simple blood test is of tremendous value. Colonoscopy is still our best tool, but too many avoid/postpone or have limited screening access. Note:  When colon cancer is found at an early stage before it has spread, the five-year relative survival rate is 91%. If the cancer has spread to distant parts of the body, the five-year relative survival rate is 14% https://lnkd.in/enACRrPw

📢 Today we announced “Thyme Care Oncology Partners” (TCOP), a dedicated platform with more than 400 oncologists nationwide to deliver provider-powered value-based cancer care. This is an important milestone for us and for the future of value-based cancer care. We believe that the only way to shift away from our entrenched fee-for-service healthcare system is by empowering oncologists as agents of change within novel payment models, allowing them to focus on delivering high-quality care in the clinic and make data-informed decisions, while Thyme Care’s oncology-trained virtual Care Team manages patients' needs between visits. Our provider-powered value-based care model aligns incentives across the healthcare ecosystem, enhancing care quality, clinical outcomes, and practice economics. Thank you to our TCOP partners for joining us in these efforts - American Oncology Network, The Center for Cancer and Blood Disorders, Southern Oncology Hematology Associates, New York Cancer & Blood Specialists, Regional Cancer Care Associates, Astera Cancer Care, and more. https://lnkd.in/gqptmriS

Geisinger Health Plan to Deploy OncoHealth for Comprehensive Cancer Care Services - HIT Consultant Geisinger Health Plan is set to implement OncoHealth, a comprehensive cancer care solution, to enhance cancer care services. The deployment of OncoHealth will revolutionize cancer care delivery at Geisinger Health Plan. #OncoHealth Implementation at Geisinger Health Plan Geisinger Health Plan will deploy OncoHealth to improve cancer care services for its patients. This comprehensive solution will streamline cancer care delivery and enhance patient outcomes. #Benefits of OncoHealth Deployment The deployment of OncoHealth at Geisinger Health Plan will bring numerous benefits, including improved coordination of care, enhanced patient engagement, and better outcomes for cancer patients. #Enhancing Cancer Care Services OncoHealth will revolutionize cancer care services at Geising ai.mediformatica.com #health #oncohealth #oncology #cancer #healthplan #cancercare #geisinger #management #platform #geisingerhealth #market #mentalhealth #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3QDSlrf)

📢 Press Release: Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services ClearNote Health has today announced the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Ovarian Cancer Test. Effective October 1, 2024, the new CPT code, 0507U, establishes a reimbursement pathway for increased patient access and broader test adoption. In addition, CMS announced that it has proposed preliminary reimbursement rate determinations for new and revised CPT codes issued by the American Medical Association (AMA), including 0507U for the Avantect Ovarian Cancer Detection Test. ClearNote Health aligned with CMS on their reimbursement recommendation of $1,160.00. “Receiving a CPT code and CMS preliminary rate recommendation for our Avantect Ovarian Cancer Test represents the second time ClearNote Health has reached a critical commercial and reimbursement milestone for our organization in less than 12 months, and most importantly, expands patient access to the early detection for ovarian cancer,” said Dave Mullarkey, CEO of ClearNote Health. 👉 Read the full press release on our website: https://lnkd.in/d-CyXp-d 🎓 The Avantect test is intended for patients at high risk for ovarian cancer, such as those with a genetic predisposed risk such as BRCA1, BRCA2, a family history of ovarian cancer, or a personal history of breast cancer before age 40. Learn more about the test on our website: https://lnkd.in/dDiNpaNr #ovariancancer #earlycancerdetection

As September comes along, an entire month dedicated to Prostate Cancer Awareness, I want to bring attention to an often overlooked aspect of cancer treatment—medication adherence. Prostate cancer affects millions of men worldwide, and even though there are advances in treatment that's provided hope and improved survival rates, the effectiveness of these treatments hinges on one critical factor: the patient’s commitment to their medication regimen. Studies have consistently shown that adhering to prescribed medications is vital in managing prostate cancer. These medications can significantly slow the progression of the disease, improve quality of life, and extend survival. But it only works if patients follow their plans consistently. This is where the Morisky Medication Adherence Scale (MMAS) plays the part. The MMAS is more than just a questionnaire—it’s a proven tool that healthcare professionals can use to assess a patient's adherence to their medication regimen. By identifying potential barriers to adherence, the MMAS helps clinicians tailor their counseling and support strategies to each patient’s needs, ensuring they stay on track with their treatment. Effective counseling, guided by tools like the #MMAS, empowers patients to take control of their health- self management of their medication taking regimen, making informed decisions that improve their outcomes. This September, as we raise awareness about prostate cancer, let’s also remember the importance of medication adherence and the tools available to support it. The fight against prostate cancer doesn’t stop with diagnosis or even with treatment; it continues with every pill taken, every regimen followed, and every life saved through vigilance and adherence. Showcasing several articles on prostrate cancer and effectiveness of medication adherence, as measured by the MMAS.

The American Lung Association's 2024 State of Lung Cancer report calls for all states to implement policies to ensure biomarker testing is included in insurance coverage. “More people with lung cancer are living longer, and that is something to celebrate. However, lung cancer is still the leading cause of cancer deaths in the US,” Harold Wimmer, president and chief executive officer of the American Lung Association, said. Read more about this year's report on Oncology Nursing News: https://lnkd.in/e7fjYF8K